Unstable Angina Differs from NSTEMI by Biomarker Status Alone. These High-Risk Features Require Urgent Catheterization.

What It Is

Unstable angina is an acute coronary syndrome (ACS) characterized by ischemic chest discomfort that is new or changing in pattern (new onset, increasing frequency or severity, or occurring at rest), without elevation of cardiac troponin above the 99th percentile of the normal reference range.

The troponin distinction is the only laboratory-based difference between unstable angina and NSTEMI. Both share the same underlying pathophysiology (plaque disruption with thrombus formation), the same management approach, and similar short-term risk. The distinction has been recognized as less clinically meaningful than previously thought as high-sensitivity troponin assays have improved: many patients classified as unstable angina by conventional troponin assay are reclassified as NSTEMI with hs-Tn.

The Three Classic Presentations

The 2000 ACC/AHA guidelines defined unstable angina through three presentations that remain clinically useful:

1. Rest angina: Angina occurring at rest, typically lasting more than 20 minutes. This is the most alarming presentation because rest pain indicates flow limitation even at minimal myocardial oxygen demand.

2. New-onset angina: Angina appearing for the first time, at least class CCS II in severity (symptoms limiting ordinary activity).

3. Increasing angina (crescendo): Previously stable angina that has become more frequent, more severe, longer in duration, or easier to provoke (occurring at lower activity levels).

The pattern of the patient above, progressing from exertional symptoms to rest symptoms over three weeks, is crescendo angina progressing to rest angina: the classic high-risk unstable angina presentation.

The Disappearing Diagnosis?

Unstable angina is becoming less common as a distinct clinical entity in the high-sensitivity troponin era. What was previously called unstable angina (troponin negative, ECG changes) is increasingly reclassified as NSTEMI when hs-Tn detects minute quantities of myocyte necrosis that conventional assays missed. In some contemporary emergency departments with routine hs-Tn use, unstable angina represents less than 5 percent of ACS presentations, with the vast majority reclassified into NSTEMI. The prognostic and management implications are currently being studied; for now, the clinical approach is similar for both.

The Mechanism

The Same Plaque, a Less Complete Thrombus

Unstable angina and NSTEMI share the same initiating event: disruption of an atherosclerotic plaque. In unstable angina, the thrombus that forms at the disrupted plaque surface is either intermittently occlusive (causing transient ischemia with complete spontaneous reopening before infarction occurs), or partially occlusive but with sufficient collateral circulation to prevent any myocyte necrosis detectable by biomarker.

The plaque biology in unstable angina is identical to that of NSTEMI: a lipid-rich vulnerable plaque with a thin fibrous cap and inflammatory infiltration. Cap disruption exposes the thrombogenic core. The only difference is that the body’s endogenous thrombolysis or the limitation of platelet-fibrin growth keeps the thrombus from occluding the artery long enough or completely enough to cause detectable cell death.

This is an unstable equilibrium. The thrombus can extend at any time. A patient with unstable angina who is not anticoagulated and antiplatelet-treated is at high risk for progression to NSTEMI or STEMI in the subsequent hours to days.

Vasospasm: Prinzmetal’s Angina

A distinct cause of rest angina is focal coronary vasospasm (Prinzmetal’s or variant angina). Unlike the atherosclerotic mechanism of typical unstable angina, vasospasm causes transient, complete coronary occlusion due to smooth muscle contraction in the coronary artery wall, producing transient ST elevation during the episode (not depression, unlike typical unstable angina) that resolves when the spasm releases.

Prinzmetal’s angina occurs predominantly at rest, often in the early morning hours, and is triggered by cold exposure, emotional stress, cocaine, and occasionally by acetylcholine. It can occur in arteries with or without atherosclerosis. The diagnosis is confirmed by provocative vasospasm testing (intracoronary acetylcholine or ergonovine). Treatment is calcium channel blockers (which relax smooth muscle) and avoidance of beta-blockers (which can precipitate vasospasm by leaving alpha-adrenergic vasoconstriction unopposed).

Microvascular Angina: When the Arteries Are Small

Coronary microvascular dysfunction (CMD) causes anginal symptoms indistinguishable from obstructive CAD but with normal epicardial coronary arteries on angiography. CMD is particularly prevalent in women and in patients with diabetes. The mechanism involves impaired vasodilatory reserve, heightened pain sensitivity to ischemia, and structural microvascular changes. It is increasingly recognized as a cause of unstable angina presentations in patients with MINOCA.

How We Diagnose

The Serial Troponin Imperative

The diagnosis of unstable angina versus NSTEMI is determined by serial troponin measurement. In patients with chest discomfort compatible with ACS:

• Conventional troponin protocol: Measure at presentation and at 6 hours. If both are below the 99th percentile, troponin is negative and unstable angina is the diagnosis.
• High-sensitivity troponin 0/1-hour algorithm: Measure at presentation and at 1 hour. A low initial hs-Tn with minimal delta (change less than predefined threshold) has a negative predictive value for NSTEMI exceeding 99 percent.
• High-sensitivity troponin 0/3-hour algorithm: An alternative that is also validated.

Any patient with ongoing ischemic symptoms and serial negative troponins should have a third measurement before ACS is definitively excluded. The troponin can be falsely negative in the first hours after symptom onset if the clinical presentation suggests very recent-onset ischemia.

ECG Findings in Unstable Angina

T-wave inversions (especially deep anterior inversions suggesting LAD disease: Wellens pattern), transient ST depression during symptoms, new LBBB during chest pain, and prolonged QTc from ischemia are the ECG findings that support unstable angina. A normal ECG does not exclude unstable angina: approximately 1 to 6 percent of NSTE-ACS patients have a completely normal presenting ECG.

Dynamic ECG changes (changes that appear with symptoms and resolve when symptoms resolve) are high-risk features that raise management urgency even when troponin is normal.

The Wellens Patterns: High-Risk LAD Ischemia

Wellens pattern A: biphasic T-waves in V2-V3, with initial positivity and terminal negativity, in a pain-free patient after ischemic symptoms. Wellens pattern B: deep, symmetrical T-wave inversions in V2-V4. Both patterns indicate critical proximal LAD stenosis and carry high short-term risk of anterior STEMI. A patient with Wellens pattern on ECG should not undergo stress testing (which can precipitate STEMI); they require direct coronary angiography.

Non-Invasive Testing in Lower-Risk Presentations

For lower-risk unstable angina presentations (patient without ongoing symptoms, negative serial troponins, ECG that has normalized), objective ischemia testing before discharge is reasonable. The options:

Exercise stress ECG. The standard treadmill test evaluates ischemia by measuring ST changes and symptom response during graded exercise. A positive result (significant ST depression at low workload, exercise-induced hypotension, or provoked typical angina) identifies patients at higher risk who benefit from coronary angiography. A negative result at high workload provides reassurance. The sensitivity for significant CAD is approximately 68 percent and specificity approximately 77 percent.

Stress echocardiography. Higher sensitivity (85 to 90 percent) than exercise ECG for detection of obstructive CAD. Provides assessment of wall motion abnormality during peak stress, which is more specific than ECG changes alone. Preferred in patients with baseline ECG abnormalities (LBBB, LVH, paced rhythm) that make ST interpretation unreliable.

Stress nuclear imaging. Single-photon emission CT (SPECT) or PET perfusion imaging. High sensitivity, particularly valuable in patients unable to exercise adequately. Pharmacological stress with adenosine, regadenoson, or dobutamine is used when exercise is contraindicated.

Coronary CT angiography (CCTA). In low-risk chest pain presentations, CCTA has emerged as a first-line diagnostic tool. The HEART Pathway and related clinical decision aids stratify low-risk patients to CCTA rather than invasive angiography, with equivalent safety and reduced cost. For unstable angina specifically, CCTA can identify the culprit plaque characteristics (high-risk plaque features on CT: low-attenuation plaque, positive remodeling, napkin-ring sign) that predict ACS risk. The PROMISE and SCOT-HEART trials established CCTA as a valid alternative to functional testing for suspected stable CAD, with a possible advantage in reducing MACE at 5 years 5 / Solid .

The Evidence

CURE: Clopidogrel in Unstable Angina

The CURE trial enrolled 12,562 patients with NSTE-ACS (including both unstable angina and NSTEMI) and randomized them to aspirin plus clopidogrel versus aspirin plus placebo. Clopidogrel significantly reduced the composite of cardiovascular death, MI, or stroke at 12 months (9.3 percent versus 11.4 percent; RR 0.80; NNT 47) 5 / Solid . CURE established dual antiplatelet therapy as the standard for NSTE-ACS.

PRISM-PLUS: GP IIb/IIIa Inhibition

The PRISM-PLUS trial enrolled 1,915 patients with unstable angina and NSTEMI randomized to tirofiban plus heparin versus heparin alone. Tirofiban (a GP IIb/IIIa inhibitor that blocks the final common pathway of platelet aggregation) significantly reduced death, MI, or refractory ischemia at 7 days (12.9 percent versus 17.9 percent; RR 0.68; p=0.004) 5 / Solid . GP IIb/IIIa inhibitors have been largely replaced in contemporary practice by ticagrelor and prasugrel, which provide superior platelet inhibition without the intravenous administration requirement, but remain available for high-risk presentations.

VERDICT: Timing in Very Early Invasive Strategy

VERDICT enrolled 2,147 NSTE-ACS patients randomized to very early coronary angiography (within 12 hours) versus standard early invasive (within 48 to 72 hours). The very early group showed no significant improvement in the primary endpoint of all-cause mortality, NSTEMI, hospital admission for refractory ischemia, or heart failure at 90 days overall. However, a prespecified subgroup of high-risk patients (GRACE score greater than 140) showed a significant benefit from very early intervention (10.7 percent versus 16.7 percent in the primary endpoint; HR 0.60; p=0.004) 5 / Solid . This reinforces the TIMACS finding: high-risk patients benefit from early angiography; lower-risk patients do not need immediate cath lab activation.

COURAGE and ISCHEMIA: Context for Medical Therapy

The COURAGE trial compared guideline-directed medical therapy (OMT) plus PCI versus OMT alone in stable coronary artery disease. PCI did not reduce death or MI compared to medical therapy 5 / Solid . ISCHEMIA confirmed this in a larger trial of stable ischemia 5 / Solid .

These trials are often misapplied to unstable angina. Unstable angina is not stable ischemia. The active plaque disruption and thrombus in unstable angina create a dynamic, high-risk situation that is fundamentally different from the fixed stenosis with stable symptoms studied in COURAGE and ISCHEMIA. The COURAGE and ISCHEMIA results do not support medical therapy alone in unstable angina; they support medical therapy for stable, carefully selected patients with known coronary artery disease who prefer not to have procedures.

The Patient Experience

The Weeks Before the Diagnosis

The most important experiential feature of unstable angina is the weeks before the emergency department visit. Most patients describe a period of denial, rationalization, and delayed recognition that spans days to weeks. The symptoms were there. They were attributed to acid reflux, aging, deconditioning, stress, or a muscle pull.

This is not a failure of intelligence. It is the result of a specific cognitive pattern in which unfamiliar, non-classic symptoms are matched against internal models (“a heart attack feels like crushing chest pain, this is pressure, so it is probably not a heart attack”). For patients without medical training, the symptom pattern of stable-to-unstable progression is not in their experiential reference library.

What patients and families need to know: any new chest discomfort, pressure, heaviness, or pain that occurs with exertion and resolves with rest, or that occurs at rest without an obvious alternative explanation, deserves prompt medical evaluation, not watchful waiting. In a person with diabetes, the chest discomfort may be absent entirely (silent ischemia) and the first symptom may be unexplained fatigue or dyspnea.

What Antiplatelet Therapy Means in Practice

After PCI for unstable angina, patients are on ticagrelor or clopidogrel for 12 months plus aspirin indefinitely. This is manageable for most patients but requires education:

• No NSAIDs without medical consultation (bleeding risk with DAPT)
• Any procedure (dental, surgical, endoscopic) requires a conversation with the cardiologist about holding P2Y12 inhibitor
• Ticagrelor causes dyspnea in approximately 15 percent of patients (a direct drug effect from adenosine release, not cardiac in origin) that often improves after the first few weeks
• Early discontinuation of DAPT increases stent thrombosis risk dramatically in the first year

Psychological Impact

Unstable angina is, from the patient’s perspective, a near-miss. The cardiologist saying “you were hours from a heart attack” is informative but not emotionally neutral. The diagnosis produces a combination of relief (I did not have the heart attack), fear (it could have been worse), and anxiety about future events (what if I have symptoms again and I am not near a hospital?).

Post-ACS anxiety and depression affect approximately 20 percent of patients after any ACS event, including unstable angina. These psychological outcomes independently predict worse cardiovascular outcomes. Screening for depression and anxiety at the 4-week post-discharge follow-up visit is guideline-recommended and frequently omitted in practice.

Decisions and Trade-Offs

Medical Therapy vs. PCI in Unstable Angina: When PCI Is Not Immediately Chosen

After coronary angiography in unstable angina, the options are:

• PCI of the culprit lesion
• Coronary artery bypass grafting (CABG) for left main disease or three-vessel disease with reduced EF where anatomy is unsuitable for PCI
• Continued medical therapy if the coronary anatomy is moderate (40 to 50 percent stenosis) or if the lesion does not appear to be the culprit for the ischemia

The ISCHEMIA subgroup analysis of patients who crossed from stable into unstable patterns has suggested that revascularization reduces hard events in unstable presentations more than in stable ones, but this remains an active research question.

The decision for CABG versus PCI in complex multivessel disease involves the SYNTAX score (an anatomical complexity score), the patient’s surgical risk, the cardiologist and surgeon’s judgment, and patient preference. The SYNTAX trial and its subgroup analyses remain the reference data for this decision 5 / Solid .

Complete vs. Culprit-Only Revascularization

For unstable angina patients with multivessel disease who undergo PCI, the decision of complete versus culprit-only revascularization (as studied in COMPLETE for STEMI) is less well-studied. Current practice generally favors treating the culprit lesion acutely and evaluating non-culprit lesions during a staged procedure based on ischemia burden.

Patients with Renal Insufficiency

Unstable angina patients with renal impairment face a specific risk: contrast nephropathy from angiography. In a patient with eGFR of 25 to 35 mL/min who presents with unstable angina, the cardiologist must balance the risk of contrast exposure against the risk of untreated unstable plaque. Standard mitigation: pre-hydration with isotonic saline, using the minimum contrast volume necessary, and pre-procedural risk discussion. N-acetylcysteine has been tested as renal protection in multiple trials and has not been shown to be effective 5 / Solid .

Spontaneous Coronary Artery Dissection: The Misclassified Unstable Angina

Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of ACS that presents identically to unstable angina on clinical evaluation: chest pain, troponin elevation or normal troponin, ST and T-wave changes. SCAD is caused by a non-traumatic, non-iatrogenic separation of the coronary arterial wall layers, creating a false lumen that compresses the true lumen.

SCAD accounts for approximately 1 to 4 percent of all ACS presentations overall but approximately 25 to 35 percent of ACS events in women under age 50. The demographics are striking: median age 42, predominantly female, often in the peripartum period or in women with fibromuscular dysplasia of the coronary or systemic arteries 5 / Solid .

The management of SCAD is the opposite of atherosclerotic ACS. Stenting in SCAD typically worsens the dissection by propagating the tear or creating further intramural hematoma under stent deployment pressure. Most SCAD cases are managed conservatively: anticoagulation to prevent thrombus propagation (though even this is debated), beta-blockers for heart rate control, and close monitoring in a monitored setting while the dissection heals. The coronary artery heals in most cases (greater than 80 percent on follow-up angiography at 30 days).

The diagnosis of SCAD requires awareness and often intravascular imaging with optical coherence tomography (OCT), which shows the characteristic intramural hematoma and intimal flap that may not be visible on angiography alone. An interventional cardiologist who places a stent in a SCAD case believing it is atherosclerotic ACS can make the outcome substantially worse.

The Diabetes Exception: Silent Ischemia and Atypical Presentation

Diabetic patients with significant coronary artery disease have a well-documented higher prevalence of silent ischemia: objective evidence of myocardial ischemia (positive stress test, ST changes during monitoring, impaired regional wall motion) without accompanying chest pain. The mechanism involves autonomic neuropathy disrupting the cardiac pain afferent system. In patients with long-standing diabetes and peripheral neuropathy, the same autonomic dysfunction affects the visceral nerve pathways that carry cardiac ischemia signals.

For the clinician, this means: a diabetic patient who presents with unexplained dyspnea, fatigue, nausea, or mild jaw or arm discomfort without chest pain may be having an ACS. The threshold for obtaining an ECG and troponin in a diabetic patient with any unexplained new symptom is lower than in a non-diabetic patient.

For the patient, the message is: if you have diabetes and you develop any new symptom you cannot explain (particularly dyspnea or fatigue with exertion), do not assume it is blood sugar or a viral illness without cardiac evaluation. The absence of chest pain does not exclude ischemia in a person with diabetes.

The High-Risk Patient Who Declines Angiography

Occasionally, a patient with high-risk unstable angina declines coronary angiography after being informed of the risks and benefits. This is the patient’s right. The cardiologist’s obligation is to document the informed refusal, improve medical therapy aggressively, and maintain a low threshold for re-evaluation if symptoms recur or worsen. Guideline-directed medical therapy in this context: aspirin, P2Y12 inhibitor, beta-blocker, high-intensity statin, ACE inhibitor or ARB (in appropriate patients), and nitrates for symptom relief.

Clinical Synthesis

Unstable angina is the last warning before the heart attack. It is the point at which all the risk factors accumulated over decades have produced a plaque vulnerable enough to disrupt, a thrombus large enough to restrict flow, and a myocardium ischemic enough to produce recognizable symptoms. The patient who arrives at the emergency department with unstable angina and receives appropriate treatment will not have his first myocardial infarction that night. But he will have it eventually, unless his underlying risk factors are addressed with the same urgency as the acute event.

This is the clinical synthesis for unstable angina: the acute event is treated in the hospital by cardiologists. The decade that preceded the acute event is what preventive cardiology addresses.

The patient in the opening of this article is a composite of thousands of real patients: a 58-year-old man with diabetes, obesity, a positive family history, an LDL-C nobody had measured in four years, a blood pressure of 148/94 that his primary care doctor was “watching,” and an exercise tolerance that had declined so gradually he had stopped noticing. A structured cardiovascular assessment would have identified every one of those risk factors. The COURAGE comparison context matters here: guideline-directed medical therapy alone is a legitimate strategy for stable CAD, but it requires that the medical therapy is actually implemented fully, that the LDL-C is at target, that the blood pressure is controlled, that the patient is on an antiplatelet agent if indicated, and that follow-up is scheduled and kept. A cardiologist-led preventive program is what makes guideline-directed medical therapy actually work in practice.

After unstable angina and PCI, the secondary prevention work is identical to post-STEMI and post-NSTEMI: DAPT adherence, statin titration to LDL-C below 70 mg/dL, blood pressure management, cardiac rehabilitation enrollment, depression screening at 4 weeks, and follow-up echocardiography.

Patients in the Chicago metro area have access to Northwestern Medicine, Rush University Medical Center, University of Chicago, and multiple other centers. Patients in central Illinois use Carle Foundation Hospital (Urbana/Champaign), OSF Saint Francis (Peoria), and Memorial Medical Center (Springfield). Rural patients in the service area may be 60 to 90 minutes from any of these centers; this program includes telemedicine-based risk factor management for patients without access to in-person subspecialty cardiology.

See also: STEMI and NSTEMI as the conditions that follow untreated unstable angina.

Mechanism Extended

The Physiology of Unstable Angina

Unstable angina (UA) is defined by the absence of biomarker elevation distinguishing it from NSTEMI, yet the underlying coronary pathophysiology is often identical: plaque disruption, superimposed thrombus, and dynamic coronary obstruction. The distinction is quantitative, not mechanistic: in UA, the ischemia is severe enough to cause symptoms and ECG changes but not severe enough or prolonged enough to cause detectable myocardial necrosis.

The implication is important: UA is not simply a mild version of NSTEMI. UA with high-risk features (ST depression greater than 2 mm in multiple leads, hemodynamic compromise, early recurrence after initial therapy) carries outcomes similar to NSTEMI. UA with low-risk features (single episode at rest with complete resolution, normal ECG, negative biomarkers) has a much more benign short-term prognosis.

The dynamic nature of unstable angina (the intermittent coronary obstruction from thrombus that partially lyses and re-forms over hours to days) is what makes it “unstable”: the next episode may be an NSTEMI or a STEMI rather than a self-terminating episode of pain.

Plaque Morphology in UA

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) studies of culprit lesions in UA demonstrate the same thin-cap fibroatheroma morphology as STEMI culprit lesions, with a large lipid core and macrophage-rich fibrous cap. The critical difference from STEMI is the degree of superimposed thrombus: UA culprit lesions typically have small, non-occlusive platelet-rich thrombi that maintain some antegrade coronary flow through the lesion.

The thrombus in UA may be “fresh” (days old, soft, platelet-aggregated) or may have organized and partially incorporated into the plaque over weeks. Serial intravascular imaging data show that UA culprit lesions can remodel over weeks with antithrombotic therapy: the thrombus resolves, the plaque surface re-endothelializes, and the stenosis severity decreases. This is part of the physiological basis for medical stabilization before invasive revascularization in selected UA patients.

Evidence Extended

CURE Trial Extended Analysis

The CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events) enrolled 12,562 patients with ACS (NSTEMI or UA with ST-segment changes) and randomized them to aspirin alone versus aspirin plus clopidogrel. The primary endpoint (cardiovascular death, MI, or stroke) was reduced from 11.4 percent to 9.3 percent (RR 0.80; p<0.001), with NNT of 48 over 9 months 5 / Solid . The benefit was consistent across subgroups defined by ST deviation, troponin elevation, and subsequent revascularization strategy.

The bleeding cost: major bleeding was increased from 2.7 percent to 3.7 percent in the clopidogrel arm (p=0.001). For most patients, the absolute ischemic benefit (2.1 percent) exceeds the absolute bleeding increase (1.0 percent), but in high-bleeding-risk patients the balance may be different.

The PCI-CURE substudy showed that the benefit of pretreatment with clopidogrel was maintained in patients who went on to receive PCI, establishing the concept of pretreatment or “loading” before catheterization.

PRISM-PLUS and the Tirofiban Evidence

The PRISM-PLUS trial (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) randomized 1,915 UA/NSTEMI patients to heparin plus tirofiban (a non-peptide GPIIb/IIIa inhibitor) versus heparin alone. Tirofiban significantly reduced the primary endpoint (death, MI, or refractory ischemia) at 7 days (12.9 percent versus 17.9 percent; p=0.004) and at 30 days 5 / Solid . This trial established GPIIb/IIIa inhibitors as effective adjunctive antiplatelet therapy in high-risk UA before the DOAC and newer P2Y12 inhibitor era.

In contemporary practice, GPIIb/IIIa inhibitors are used more selectively than in the PRISM-PLUS era, primarily as “bailout” therapy during PCI for large thrombus burden, no-reflow, or dissection during the procedure, rather than as routine medical pretreatment. The reason for this shift: the combination of dual antiplatelet therapy (aspirin plus ticagrelor or prasugrel) achieves platelet inhibition deep enough to make routine upstream GPIIb/IIIa inhibition largely redundant, while adding substantial bleeding risk.

VERDICT Trial: Very Early Versus Deferred Intervention

The VERDICT trial (Very EaRly versus Deferred invasive evaluation using Computerized Tomography in patients with non-ST-segment elevation ACS) randomized 2,147 NSTE-ACS patients to very early invasive strategy (angiography within 12 hours) versus standard early invasive (within 48 to 72 hours). No significant difference in 90-day major cardiovascular events was observed in the overall population, but a significant reduction was seen in the very high-risk subgroup (GRACE score above 140) who received very early intervention 5 / Solid .

VERDICT confirms the risk-stratified urgency framework: immediate strategy for very high-risk UA/NSTEMI (GRACE above 140, hemodynamic instability, refractory ischemia), early invasive within 24 hours for high-risk, delayed invasive within 72 hours for lower-risk patients.

COURAGE Extended Analysis: Medical Therapy Versus PCI in Stable Disease

The COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) randomized 2,287 patients with stable angina and documented obstructive CAD to guideline-directed medical therapy (OMT) alone versus PCI plus OMT. No significant reduction in death or MI was found with PCI versus OMT (19.0 percent versus 18.5 percent; p=0.62) at 4.6 years of follow-up 5 / Solid .

The COURAGE trial’s relevance to UA is indirect but important: it establishes that in stable coronary artery disease (which is what some UA patients are found to have after medical stabilization), revascularization is not superior to aggressive medical therapy for hard outcomes. This informed the conservative approach to lower-risk UA that is supported by current guidelines.

The ISCHEMIA trial (2019) confirmed and extended COURAGE: in patients with stable ischemic heart disease and moderate-to-severe ischemia on stress testing, an initial invasive strategy versus conservative management produced no significant reduction in cardiovascular death or MI over a mean 3.2 years 5 / Solid . The exception in ISCHEMIA: patients with left main disease greater than 50 percent and those with unacceptable angina despite medical therapy benefited from revascularization.

Patient Experience Extended

Recognizing UA at Home

The patient with UA has an unusual challenge: the symptoms are real, they are caused by significant coronary artery disease, but they may resolve spontaneously over minutes to tens of minutes. In the interval between symptom onset and arrival at the emergency department, the pain may have completely resolved. A patient who drove himself to the emergency department because he had crushing chest pain at rest for 10 minutes that then resolved is a patient with UA until proven otherwise, even though he is pain-free on arrival and his first ECG and troponin are normal.

Patients who have previously been diagnosed with stable angina and have been managing it with short-acting nitroglycerin for 5 years need to understand the specific features that distinguish their stable predictable exertional pattern from UA: rest pain (occurring without provocation), pain that is more severe than usual, pain lasting longer than 20 minutes without complete resolution, pain requiring more than two nitroglycerin tablets without relief. These are the features that require emergency evaluation.

The practical instruction: “If your nitroglycerin does not completely relieve your chest pain within 10 to 15 minutes, or if you have used three nitroglycerin tablets without complete relief, or if your pain occurs at rest and feels different or more severe than your usual angina, call 911. Do not drive yourself.”

Diagnostic Conversations About Uncertain Risk

A patient presenting with possible UA often faces a situation where the physician is uncertain: the history is consistent with UA, but the initial ECG is normal and the first troponin is negative. The clinical conversation must manage this uncertainty honestly.

“Based on your symptoms, particularly that the pain occurred at rest and lasted 20 minutes, I am concerned this could be related to your heart arteries. Your ECG is normal right now and your first blood test shows no damage to heart muscle. We will check the blood test again in one to two hours. If both tests remain negative and you feel better, we may be able to discharge you with close follow-up, but if the tests change or your pain returns, we will need to do further testing.”

This communication gives the patient a framework, a timeline, and a contingency plan, without prematurely reassuring them that everything is fine.

The Psychosocial Impact of Recurrent UA Episodes

Patients with recurrent UA over years (multiple emergency presentations with relief by medical therapy each time, without proceeding to revascularization either by anatomy or by patient choice) develop a distinctive psychological adaptation that ranges from healthy vigilance to anxiety disorder.

Some patients become hypervigilant: every instance of chest tightness, whether from musculoskeletal, gastrointestinal, or true anginal origin, triggers an emergency department visit. This is appropriate if the patient’s clinical history genuinely makes it difficult to distinguish stable and unstable symptoms. It is debilitating if the patient is responding to non-cardiac chest pain with the same intensity.

Cognitive behavioral therapy (CBT) for cardiac anxiety has been evaluated in small trials and shows benefit for reducing emergency health-seeking behavior and improving quality of life in patients with recurrent cardiac symptom presentations 3 / Early . Cardiologists managing recurrent UA should be aware that psychiatric and psychological support may be as important as pharmacological improvement.

Decisions Extended

Wellens Syndrome: A Pattern That Must Not Be Missed

Wellens syndrome describes a specific ECG pattern in patients who have had an episode of UA that has resolved. In the pain-free state, the ECG shows distinctive T-wave changes in leads V2-V3 (and sometimes V4-V5) that indicate a recently ischemic but now reperfused proximal LAD territory.

Two patterns exist: Type A (biphasic T-waves with initial small positive deflection followed by deep inversion) and Type B (deeply symmetric inverted T-waves, larger amplitude). Both patterns represent subepicardial injury from severe proximal LAD ischemia that has transiently resolved.

The clinical trap: a patient with Wellens pattern is pain-free, may have a normal or near-normal troponin (if the ischemia was not prolonged enough to cause necrosis), and may have a near-normal resting LVEF on echocardiography. Sending this patient home with stress testing as a follow-up plan is dangerous: the Wellens pattern is a contraindication to provocative stress testing because the LAD territory is ischemic at rest and exercise-induced ischemia may precipitate MI or VF.

Wellens pattern is an indication for urgent invasive coronary angiography, not stress testing. The majority of patients with Wellens syndrome have a critical proximal LAD stenosis (typically 80 to 95 percent occlusion) that requires revascularization. Without revascularization, the 30-day risk of LAD territory STEMI is high 4 / Promising .

Emergency physicians and cardiologists must recognize this pattern. Educational presentations on Wellens syndrome are a recurring theme in cardiology conference programs because recognition failures leading to missed high-risk LAD disease continue to be documented.

The Decision to Proceed Without PCI

After UA, some patients are found to have coronary anatomy that is not amenable to PCI (diffuse three-vessel disease without a clear dominant culprit, high SYNTAX score, technical features that make PCI high-risk). The cardiology team faces the decision between CABG (coronary artery bypass grafting) and guideline-directed medical therapy.

The SYNTAX score quantifies anatomical complexity of CAD and stratifies which revascularization strategy (PCI versus CABG) is preferable. SYNTAX scores below 22 favor PCI; scores above 32 favor CABG for three-vessel disease 5 / Solid . Left main disease with SYNTAX below 32 is a PCI-eligible anatomy; SYNTAX above 32 favors CABG.

After UA is medically stabilized, the urgency of the revascularization decision is lower than in STEMI. A patient with anatomically complex three-vessel disease identified at catheterization during an admission for UA can be medically stabilized, the anatomy discussed at a multidisciplinary heart team meeting, and a scheduled CABG performed within 1 to 4 weeks in a semi-elective setting. This “bridge with medical therapy” approach applies standard antithrombotic therapy (dual antiplatelet therapy until the surgical plan is clear, then stopping the P2Y12 inhibitor 5 to 7 days before CABG if that is the plan), improves other cardiovascular risk factors, and allows the patient to participate in the decision between PCI and CABG.

Colchicine After ACS: New Evidence

The COLCOT trial (2019) randomized 4,745 patients within 30 days of MI to colchicine 0.5 mg daily versus placebo. Colchicine significantly reduced the primary composite endpoint of cardiovascular death, cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization (5.5 percent versus 7.1 percent; HR 0.77; p=0.02) 5 / Solid . The LoDoCo2 trial confirmed a similar benefit in patients with established stable CAD 5 / Solid .

Colchicine’s mechanism in ACS appears to be its inhibition of neutrophil activation and NLRP3 inflammasome activity, reducing the inflammatory amplification of plaque vulnerability after an acute event. These trials established colchicine as a potential addition to post-ACS secondary prevention, though it is not yet universally adopted in practice, partly because the absolute risk reduction is modest and the long-term safety data for colchicine in cardiovascular disease (outside the pericarditis context where long-term use is well-characterized) is still accumulating.

The 2023 ESC NSTEMI guidelines give colchicine a Class IIa recommendation in post-ACS patients with residual inflammatory risk 5 / Solid . This represents a meaningful evolution of secondary prevention therapy beyond the traditional lipid-blood pressure-antiplatelet triad.

Evidence Extended

The VERDICT Trial: Full Analysis

The VERDICT (Very EaRly versus Deferred invasive evaluation using Computerized Tomography) trial enrolled 2,147 patients with NSTE-ACS at 6 Danish centers. The study design was specifically powered to detect whether immediate angiography (less than 12 hours) was superior to deferred angiography (48 to 72 hours) for the primary composite endpoint (all-cause death, non-fatal NSTEMI, hospital admission for refractory ischemia, or hospitalization for heart failure) at 90 days.

Overall population result: no significant difference (15.8 percent versus 17.6 percent; HR 0.90; 95% CI 0.74-1.10; p=0.30) 5 / Solid . The high-risk subgroup result (GRACE above 140): 13.9 percent versus 21.0 percent (HR 0.64; 95% CI 0.43-0.95; p=0.03), confirming that GRACE score above 140 identifies the patient who benefits from immediate intervention.

A secondary finding from VERDICT that is underappreciated: CCTA as a pre-catheterization triage tool significantly reduced rates of normal coronary arteries found at invasive angiography (4 percent in CCTA-triaged versus 19 percent in standard triage; p<0.001). This supports CCTA as an appropriate gatekeeping tool for invasive angiography in intermediate-risk UA/NSTEMI presentations.

CURE Trial: Subgroup Analysis by Treatment Strategy

The CURE trial enrolled patients before the era of universal invasive management. In the subgroup who received PCI (the PCI-CURE substudy), pretreatment with clopidogrel significantly reduced 30-day death, MI, or urgent revascularization compared to placebo (4.5 percent versus 6.4 percent; RR 0.70; p=0.03) 5 / Solid 06812-8). This established the concept of “pretreatment” with P2Y12 inhibitors before PCI in ACS.

However, the timing of P2Y12 inhibitor loading relative to PCI is an unresolved question. Loading with ticagrelor or prasugrel at the time of PCI (“peri-procedural” treatment) versus 12 to 24 hours before (“pretreatment”) has been compared in multiple trials with conflicting results. The current consensus from the 2023 ESC NSTEMI guidelines is that loading the P2Y12 inhibitor at the time of diagnostic angiography (when the coronary anatomy is known and PCI is planned) is preferred over routine pretreatment before angiography, because some patients will require CABG and pretreatment exposes them to surgery on a platelet-inhibited state with higher bleeding risk.

Patient Experience Extended

The Recurrent Pain Pattern and Differential Diagnosis

Patients with UA often have a history of prior stable angina that has changed in character. Understanding the progression from stable to unstable is important for both the physician and the patient.

Stable angina has three characteristics: predictable (occurs with the same level of exertion each time), reproducible (the same activity reliably triggers symptoms), and relieved by rest or nitroglycerin within 3 to 5 minutes. These three features tell the cardiologist that the coronary flow reserve is compromised but adequate at rest; the patient has significant CAD but no acute plaque event.

Unstable angina has broken at least one of these features: new rest pain (coronary flow reserve now compromised even at rest), pain that is worse than usual for a given level of activity (the stenosis has acutely worsened), or pain that requires more nitroglycerin to relieve (the underlying physiological disturbance is greater).

This functional framework for distinguishing stable and unstable angina is more practically useful than the formal ACC/AHA classification (Braunwald classification) in most patient communication. Teaching patients to recognize the transition from their “usual” angina pattern to “something different” enables them to seek care at the appropriate level of urgency.

A common pitfall: patients who have had stable angina for years become habituated to their symptoms and may not report the worsening as significant because “it is the same thing I always have.” A clinical encounter that systematically asks “Has this episode been different from your usual angina in any way?” will catch UA presentations that a symptom-focused question (“have you had any chest pain?”) might miss.

The Patient on Full Guideline-Directed Therapy Who Still Has Angina

A patient with established CAD who has previously been revascularized (by PCI or CABG), is on maximal medical therapy (aspirin, statin, beta-blocker, nitrate), and continues to have UA episodes represents a refractory angina scenario. The revascularization options may have been exhausted (anatomy not suitable for further PCI or CABG), and the patient’s quality of life is significantly impaired.

Therapies for refractory angina beyond standard revascularization include:

• Enhanced External Counterpulsation (EECP): Non-invasive therapy using cuffs that apply sequential external compression to the lower extremities during diastole (timed to the cardiac cycle). Multiple trials show reduction in angina frequency and improved exercise tolerance, with a mechanism involving enhanced coronary collateral development and improved endothelial function 4 / Promising . EECP is covered by Medicare for refractory angina.
• Ranolazine: An antianginal agent that inhibits the late sodium current in ischemic cardiomyocytes (reducing calcium overload and improving diastolic relaxation). Reduces angina frequency by approximately 30 percent compared to placebo in patients with refractory angina 5 / Solid . Does not affect heart rate or blood pressure, which distinguishes it from other antianginal agents.
• Neurostimulation (spinal cord stimulation): An implanted epidural lead that delivers electrical stimulation to the dorsal columns of the spinal cord, modulating pain perception and possibly improving microvascular function in ischemic areas. Used at specialized centers for refractory angina unresponsive to other treatments 4 / Promising .

Decisions Extended

Dual Antiplatelet Therapy Duration: The Risk-Benefit Calibration

After UA treated with PCI and drug-eluting stent, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is prescribed for 12 months. The 12-month duration represents a balance between stent thrombosis prevention (which requires DAPT) and bleeding risk (which accumulates with DAPT duration).

The DAPT study showed that extending DAPT beyond 12 months to 30 months in DES recipients reduced stent thrombosis (0.4 percent versus 1.4 percent; p<0.001) and MACE but increased bleeding 5 / Solid . The absolute ischemic benefit was greatest in patients with prior MI; the absolute bleeding increase was similar across risk groups. High-risk patients (prior MI, complex coronary anatomy, reduced LVEF) benefit most from extended DAPT.

Short DAPT (1 to 3 months followed by aspirin monotherapy or P2Y12 monotherapy) has been evaluated in patients with high bleeding risk who cannot safely maintain 12 months of DAPT. The STOPDAPT-2, TWILIGHT, and MASTER DAPT trials demonstrate that abbreviated DAPT followed by P2Y12 monotherapy (stopping aspirin) reduces bleeding without significantly increasing ischemic events in selected populations 5 / Solid .

The practical decision: for a UA patient at standard ischemic risk without high bleeding risk, 12 months of DAPT followed by aspirin monotherapy is standard. For a patient at high ischemic risk (prior MI, complex PCI, prior stent thrombosis, diabetes), extended DAPT to 30 months is a shared decision-making conversation. For a patient at high bleeding risk (recent GI bleed, anticoagulation required for atrial fibrillation, thrombocytopenia), abbreviated DAPT with early aspirin discontinuation at 1 to 3 months followed by P2Y12 monotherapy is the appropriate approach.

The Communication Between Emergency Physician and Cardiologist

The emergency physician who identifies UA and calls the cardiologist is communicating a time-sensitive clinical situation. The quality of that communication determines what happens next.

A structured communication format for UA:

1. Patient identifier: Name, age, room number
2. Clinical status: Currently stable versus actively deteriorating; heart rate and blood pressure
3. Presenting complaint: Type of chest pain, duration, triggers
4. Relevant history: Prior CAD, prior PCI/CABG, known left main disease
5. Key objective data: ECG (specific changes: ST depression in V4-V6, new LBBB, Wellens pattern), troponin result and trend, LVEF if known
6. Medications already given: Aspirin dose, anticoagulation administered
7. Specific question: Requesting risk stratification guidance, requesting urgent catheterization, or requesting to discuss conservative management plan

This structured handoff eliminates the ambiguity that leads to either delayed intervention (cardiologist who was called for “chest pain” does not understand the urgency) or over-triage (cardiologist who is called for every chest pain in the ED regardless of clinical probability).

The SBAR (Situation, Background, Assessment, Recommendation) format used for clinical communication in many hospital systems applies directly to this handoff. Training emergency teams on UA-specific SBAR communication is a quality improvement intervention that reduces door-to-catheterization time in observational studies.

Advanced Management and Refractory Disease

9.1 When Guideline-Directed Medical Therapy Is Not Enough

The COURAGE trial and the subsequent ISCHEMIA trial established a foundational principle: for patients with stable ischemic heart disease, a strategy of guideline-directed medical therapy alone is non-inferior to routine revascularization for preventing death or MI 5 / Solid . This principle does not apply to unstable angina. Unstable angina represents an active, vulnerable coronary plaque state where guideline-directed medical therapy alone is insufficient to prevent progression to MI.

The problem that emerges in practice is the patient on complete guideline-directed medical therapy who continues to have recurrent rest pain. She is on aspirin, ticagrelor, atorvastatin 80 mg, metoprolol, long-acting nitrate, and a calcium channel blocker. Her BP is controlled. Her LDL-C is 45 mg/dL. She was revascularized six months ago with two drug-eluting stents. And she is still having chest pain with minimal exertion and occasionally at rest.

In this patient, the differential is not “more of the same.” The differential is:

1. In-stent restenosis: IVUS or OCT at repeat angiography can confirm or exclude.
2. Progression of disease in non-stented segments: repeat coronary CTA or catheterization.
3. Coronary vasospasm as a co-existing mechanism: provocation testing.
4. Microvascular disease: CFR and IMR measurement at catheterization.
5. Non-cardiac chest pain: musculoskeletal, esophageal spasm, anxiety-related somatic symptoms.

Each of these has a distinct management path. The error is to attribute persistent symptoms in a revascularized patient to anxiety or “non-cardiac” etiology without systematic exclusion of the above.

9.2 Refractory Angina: Specific Therapies Beyond Standard Care

Refractory angina is defined as chronic angina in patients who have exhausted revascularization options and remain symptomatic on maximally tolerated medical therapy 5 / Solid . An estimated 600,000 to 1.8 million Americans live with refractory angina, though systematic registry data are limited 3 / Early .

Ranolazine (Ranexa): Late sodium current inhibitor that reduces intracellular calcium overload in ischemic myocytes. The MERLIN-TIMI 36 trial showed ranolazine reduced recurrent ischemia in NSTE-ACS patients (HR 0.87, 95% CI 0.76-0.98) without reducing death or MI 5 / Solid . In chronic angina, ranolazine reduces angina frequency by roughly one episode per week and improves exercise duration 5 / Solid . It does not reduce mortality. It does not interact with most standard cardiac medications. It modestly prolongs QTc and requires caution in patients on other QTc-prolonging agents. Dose: 500 mg to 1000 mg twice daily.

Enhanced External Counterpulsation (EECP): A non-invasive procedure applying sequential pneumatic compression to the lower extremities during diastole, mechanically augmenting coronary perfusion pressure. The MUST-EECP trial randomized 139 patients with chronic angina 5 / Solid 00016-7). Active EECP produced a significant increase in time to ST-segment depression on treadmill testing compared to sham. Symptom reduction was clinically meaningful. The effect is durable at two years in observational follow-up. EECP is approved by FDA (Class II 510(k)) for refractory angina. It requires 35 one-hour sessions over seven weeks. Medicare covers it for Class III or IV CCS angina that has failed medical therapy and revascularization.

Spinal Cord Stimulation (SCS): Epidural electrodes at C7-T1 deliver low-voltage current that suppresses pain signaling and reduces sympathetic tone. Multiple small RCTs and registry studies demonstrate significant angina frequency reduction and quality-of-life improvement 4 / Promising 90166-X). SCS does not appear to mask true ischemic pain while allowing MI to proceed silently: ambulatory monitoring data show that objective ischemia is reduced, not just pain perception 3 / Early . SCS requires neurosurgical implant and is available at academic centers including Northwestern Memorial Hospital in Chicago and the University of Illinois Chicago.

Transmyocardial Laser Revascularization (TMR): A surgical technique drilling channels into the myocardium, intended to promote angiogenesis. Early RCTs showed symptom benefit without survival benefit 5 / Solid . The mechanism of benefit appears to be denervation rather than angiogenesis. TMR is available at selected surgical centers and is not widely offered. It remains an option for patients who are not candidates for EECP or SCS.

9.3 Wellens Syndrome Revisited: Recognition Saves Lives

Wellens syndrome deserves sustained emphasis because the failure to recognize it kills patients. The original 1982 description by de Zwaan and Wellens identified a pattern of deep symmetric T-wave inversions in V2-V3 (Type B) or biphasic T-waves in V2-V3 (Type A) in patients who had recent rest chest pain but were currently pain-free with normal or minimally raised troponin 5 / Solid 90462-X).

The physiological substrate is critical stenosis of the proximal LAD with spontaneous reperfusion. The characteristic ECG appears during the pain-free, reperfused period. The error made in emergency medicine and cardiology triage is this: the patient is pain-free, the ECG “shows T-wave inversions” (without pattern recognition), and the troponin is negative or borderline. She is admitted for observation and scheduled for stress testing.

Stress testing in Wellens syndrome is contraindicated. Exercise in the presence of critical proximal LAD stenosis can precipitate anterior STEMI. The appropriate management is immediate inpatient admission with coronary angiography within 24 hours. The pattern on the ECG is a roadmap to the culprit lesion before the artery occludes.

Every clinician who practices in the emergency setting or admits chest pain patients should be able to draw the Wellens ECG pattern from memory. Type A (biphasic T in V2-V3): the T wave deflects upward, then inverts. Type B (symmetric deep inversion in V2-V3): the T wave is deeply and symmetrically negative, resembling what you would see after a completed anterior MI. The key differentiator from completed MI: no Q-wave in V2-V3 in Wellens. The ST segment is either normal or minimally raised.

Building Wellens pattern recognition into the triage process at rural and community hospitals in Illinois requires both education and system-level change. clinical case files will include a dedicated Wellens case for this reason. The difference between recognition and non-recognition in this syndrome is not a statistical abstraction: it is whether a patient leaves the hospital alive.

9.4 Anti-Inflammatory Therapy: COLCOT and COPE-2

The understanding of unstable angina has evolved to incorporate coronary inflammation not just as a trigger of plaque rupture but as a treatable target in secondary prevention. The COLCOT trial randomized 4,745 patients within 30 days of MI to colchicine 0.5 mg daily versus placebo 5 / Solid . At a median 23 months of follow-up, colchicine reduced the primary composite of death from cardiovascular causes, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina by 23 percent (HR 0.77, 95% CI 0.61-0.96). The number needed to treat was 44 patients over two years to prevent one event.

The LoDoCo2 trial extended this finding to chronic coronary disease: 5,522 patients with stable coronary disease were randomized to colchicine 0.5 mg daily versus placebo 5 / Solid . Colchicine reduced the composite of cardiovascular death, MI, stroke, or ischemia-driven revascularization by 31 percent (HR 0.69, 95% CI 0.57-0.83). Non-cardiovascular mortality was numerically higher in the colchicine group (0.7% vs 0.5%), a signal that has not been explained mechanistically and remains an area of ongoing surveillance.

Colchicine 0.5 mg daily costs approximately $30 to $60 per month on generic pricing and is well-tolerated in most patients. The most common side effect is diarrhea, occurring in 10 to 15 percent, typically manageable with dose reduction or food administration. Colchicine is renally cleared and should be used with caution in patients with eGFR below 30 mL/min.

The clinical implication for unstable angina management is direct: in the acute phase, anti-inflammatory therapy with colchicine can be initiated at or shortly after the time of angiography, alongside standard DAPT and statin therapy. It does not replace antiplatelet therapy. It adds an inflammatory axis component that the standard secondary prevention stack does not address.

9.5 Patient Communication: What Changes After an Unstable Angina Episode

A patient who has survived an episode of unstable angina has, in most cases, been told that she was “lucky” or that “it wasn’t a heart attack.” This framing, while technically accurate, is harmful. Unstable angina is not a near-miss. It is an active, unstable phase of coronary artery disease that carries a 1.7 percent 30-day mortality rate and a 12 percent composite of death or MI at six months in contemporary registries 5 / Solid .

The conversation that must happen at discharge has four components:

First, what the diagnosis means: “You have coronary artery disease with an unstable phase. This is serious. The event you had could have become a heart attack. The medications and the catheterization were designed to prevent that.”

Second, what symptoms require immediate return: Any rest pain lasting more than five minutes, any exertional pain worse than baseline, any syncope, any diaphoresis with chest pressure. The patient should have a clear, practiced action plan: nitroglycerin sublingual, wait three minutes, repeat if no relief, call 911. Not “call the office.” Call 911.

Third, medication instructions with costs acknowledged: If ticagrelor is prescribed and costs $180 per month after insurance, say so. Provide the AstraZeneca copay card number and website at discharge. “I am prescribing this medication because it is the strongest antiplatelet agent for your situation. If you cannot afford it, call us before you stop taking it. Stopping suddenly after coronary stenting is one of the most dangerous things that can happen.”

Fourth, the cardiac rehabilitation conversation: Not an afterthought in the discharge papers. A direct spoken conversation: “I am referring you to cardiac rehabilitation. It is one of the most effective treatments for preventing another episode. The data show it reduces death and repeat events by 20 to 25 percent. Your body has been through a significant stress and structured exercise in a monitored setting is safer than trying to resume activity on your own.”

This is not performed empathy. This is conveying the clinical stakes with specificity, which is the Mogire register.

Dr. Job Mogire, MD FACP FACC. Carle Foundation Hospital; Carle Illinois College of Medicine. Stop Dying Early.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.